CD274 and cervical carcinoma: This new insight into the tumoral microenvironment highlights meaningful prognostic markers and emphasizes the need for targeted immunotherapeutic strategies that leverage the presence and activity of CD8+ TILs and PD-L1 expression to improve clinical outcomes in cervical cancer patients.